FOXO Technologies Expands Share Authorization and Preferred Terms

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialThe latest update is out from FOXO Technologies ( (FOXO) ). On December 16, 2025, FOXO Technologies amended the terms of its Series B and Series C cumulative convertible redeemable preferred stock, revising the conversion price formula to the higher of $0.0001 or 90% of the average volume-weighted average price over the five trading days prior to conversion, removing the mandatory conversion provision, and exempting dividends paid to holders of its Series E cumulative redeemable secured preferred stock from certain restrictions. On the same date, majority stockholder Rennova Health, Inc., controlled by FOXO’s CEO, used its approximately 98.6% voting control to approve, by written consent, an increase in authorized Class A common shares from 2.5 billion to 10 billion and preferred shares from 10 million to 20 million, to be effected at the board’s discretion before April 30, 2026, as well as the re-election of the existing board and the non-binding ratification of Kreit & Chiu CPA LLP as auditor for 2025, moves that significantly expand FOXO’s capital-raising flexibility and consolidate existing governance and oversight structures ahead of potential future financing or strategic actions. Spark’s Take on FOXO Stock According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform. FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company. To see Spark’s full report on FOXO stock, click here. More about FOXO Technologies FOXO Technologies Inc. is a Delaware corporation active in the public markets, with a capital structure that includes multiple classes of common and preferred stock, including Series B, C, and E preferred shares, and is controlled, in voting terms, by Rennova Health, Inc., which holds approximately 98.6% of its voting rights as of December 16, 2025. Technical Sentiment Signal: Sell Current Market Cap: $131.2K Find detailed analytics on FOXO stock on TipRanks’ Stock Analysis page.